• Client Login
Ozmosi
  • Services
    • BEAM Clinical Trial Data
    • GCT Global Clinical Trials
    • PRYZM Pharma Product Database
    • PDUFA Calendar
    • KRYSTL Industry Scan Reporting
    • LENZ Company Pipeline Summary
    • Specialized Consulting
    • Approved Pharmaceutical Products in Use
  • About Us
  • Case Studies
  • Newsroom
  • Contact Us
Select Page
Merck Diabetes Pipeline Analysis

Merck Diabetes Pipeline Analysis

Apr 21, 2025 | Business, Data Analytics, Diabetes, Disease Area Trends

Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
Novo Nordisk Diabetes Pipeline Analysis

Novo Nordisk Diabetes Pipeline Analysis

Apr 21, 2025 | Chronic Disease, Diabetes, Disease Area Trends

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
The Future of Innovation in Diabetes & Heart Disease

The Future of Innovation in Diabetes & Heart Disease

Apr 21, 2025 | Chronic Disease, Diabetes, Disease Area Trends, Heart Disease

When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role.  New blockbuster drugs are the lifeblood of pharmaceutical companies.  Traditionally, they...
What do the big players have in store for the Diabetes market in the next 12 months?

What do the big players have in store for the Diabetes market in the next 12 months?

Apr 21, 2025 | Chronic Disease, Diabetes, Disease Area Trends

Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next...
ELI LILLY in the Diabetes Market

ELI LILLY in the Diabetes Market

Apr 21, 2025 | Business, Chronic Disease, Diabetes, Disease Area Trends

For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...

Recent Posts

  • How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%May 12, 2025
  • Market Overview: GLP-1 Agonists and the Obesity MarketMay 12, 2025
  • Not Your Grandparents’ Probability of Success ForecastsMay 5, 2025
  • Clinical Trial Success Rates: What Makes Some Companies Stand Out?May 5, 2025
  • Using Data to Optimize Clinical Trial RecruitmentApril 24, 2025
  • FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug DevelopmentApril 24, 2025
  • Home
  • About Us
  • Services
  • Case Studies
  • Newsroom
  • Contact Us
  • Facebook
  • X
OZMOSI© 2024 | All Rights Reserved | Site by Webtyde